C hronic and acute stress to the heart results in a pathological remodeling response accompanied by cardiomyocyte hypertrophy, fibrosis, pump failure, myocyte degeneration, and apoptosis, which often culminate in heart failure and sudden death. 1 Although classic pharmacological treatment strategies can reduce remodeling and prolong survival in heart failure patients, these therapies are ultimately ineffective in preventing progression of the disease. A hallmark of pathological hypertrophy and heart failure is the reactivation of a set of fetal cardiac genes, including those encoding atrial natriuretic factor, B-type natriuretic peptide, and fetal isoforms of contractile proteins such as skeletal ␣-actin and Myh7 (␤-myosin heavy chain). 2 Downregulation of Myh6 (␣-myosin heavy chain) and upregulation of Myh7 are common responses to cardiac injury regardless of the species. [3] [4] [5] Relatively minor increases in the ratio of Myh6 to Myh7 have been shown to have beneficial effects on cardiac contractility and performance in humans and rodents. 6 -8 
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Previously, we and others identified signature expression patterns of microRNAs (miRNAs) associated with pathological cardiac hypertrophy, heart failure, and myocardial infarction in humans and in mouse models of heart disease (reviewed elsewhere 9 ). Gain-and loss-of-function studies in mice have revealed profound and unexpected functions for these miRNAs in numerous facets of cardiac biology, including the control of myocyte growth, contractility, and fibrosis (reviewed by Montgomery et al 10 ). Especially intriguing is miR-208, an miRNA encoded within an intron of the Myh6 gene, which regulates the cardiac stress response. 11, 12 Although genetic deletion of miR-208 in mice failed to induce an overt phenotype at baseline, in response to several forms of cardiac stress, miR-208 -null mice showed virtually no cardiomyocyte hypertrophy or fibrosis and were unable to upregulate Myh7 expression. 11, 12 In the adult heart, miR-208 is essential for the expression of not only Myh7, but also a closely related myosin isoform, Myh7b. 12, 13 Remarkably, both of these genes encode slow myosins and contain intronic miRNAs (miR-208b and miR-499, respectively). 14, 15 Because miR-208 (called miR-208a here), miR-208b, and miR-499 are related miRNAs that arise from myosin genes, we collectively refer to these miRNAs as MyomiRs. 16 Through gain-and loss-of-function experiments in mice, we have shown that genetic deletion of miR-208a dose-dependently reduces Myh7b/miR-499 expression within the adult heart. 13 Because miR-499 -mutant animals show no effect on Myh7 expression or cardiac remodeling in response to stress and reintroduction of miR-499 removes the cardiac effects seen in the miR-208a-mutant mice, 13 we conclude that the combined reduction in miR-208a and miR-499 is responsible for the cardioprotective effects seen in miR-208a-mutant animals.
The importance of miRNAs for cardiac function and dysfunction suggests opportunities for therapeutically exploiting the biology of miRNAs in the setting of heart disease. Single-stranded oligonucleotides have been shown to be effective in inactivating miRNAs in vivo [17] [18] [19] [20] [21] and represent a potentially effective means of inactivating pathological miRNAs. Here, we show that systemic delivery of locked nucleic acid (LNA)-modified antisense oligonucleotides against miR-208a is sufficient to induce specific, potent, and sustained silencing of miR-208a in the heart. Moreover, antimiR-208a dose-dependently blunts stress-induced remodeling, functional deterioration, and cardiac myosin switching while improving general health and survival in a rat model of diastolic heart failure (Dahl salt-sensitive rats). Gene expression analysis showed specific gene expression changes in response to antimiR-208a treatment, including changes in previously defined target genes. Intriguingly, these physiological effects of antimiR208a in hypertensive rats are mirrored by significant changes in plasma levels of circulating miRNAs. Together, these studies indicate the potency of systemically delivered anti-miRs in the settings of heart disease and validate miR-208 as an important therapeutic target during heart failure.
Methods

Animal Procedures
All animal protocols were approved by the Institutional Animal Care and Use Committee of miRagen Therapeutics, Inc.
Animals and Delivery of Locked Nucleic Acid-Modified Anti-miRs
The LNA-anti-miR oligonucleotides were synthesized at miRagen Therapeutics, Inc. as fully phosphorothiolated oligonucleotides perfectly complementary to the 5Ј region of the mature miR-208a sequence. For the dose response in Figure 1 , a mismatch antimiR-208a control was used that contained 3-bp mismatches (5Ј-CtttGTgCtCGtAtGA-3Ј; upper case indicates LNA; lower case, DNA). For all subsequent experiments, we used a universal control with identical chemistry. This LNA control oligonucleotide consisted of a sequence directed against a Caenorhabditis elegans-specific miRNA (5Ј-TccTAgAAaGAgtAgA-3Ј; upper case indicates LNA; lower case, DNA). Unless indicated otherwise, in vivo delivery of the oligonucleotide chemistries was achieved by low-pressure intravenous injections via the tail vein of either adult male C56Bl6 mice or adult male Dahl salt-sensitive rats (Harlan, Indianapolis). All chemistries were dissolved and injected in a comparable end volume of saline, after which the animals were examined for obvious side effects of the chemistries. Tissue samples were collected at the indicated time points for molecular or histological examination. Dahl rats were maintained on 0.25 NaCl or placed on 4% or 8% NaCl diet at 8 weeks of age (Harlan, Indianapolis, IN). -208a) . B, Real-time polymerase chain reaction analysis on murine hearts 1 week after intravenous delivery of increasing doses of antimiR-208a shows a dose-dependent reduction in miR208a levels. C, Northern blot analysis on total RNA from murine hearts 1 week after intravenous delivery of antimiR208a shows a dose-dependent reduction in miR-208a detection, whereas a control mismatch chemistry (MM) has no effect on miR-208a. U6 serves as a loading control. D, Realtime polymerase chain reaction analysis on cardiac tissue collected at the indicated time points shows that intravenous, intraperitoneal, or subcutaneous delivery of 25 mg/kg antimiR-208a induces potent silencing of miR-208a. In B and D, error bars depict SEM (nϭ4 for each time point and dose).
Quantitative Real-Time Polymerase Chain Reaction Analysis
For in vivo real-time polymerase chain reaction (RT-PCR) analysis, RNA was extracted from cardiac tissue with Trizol (Invitrogen); then, 2 g RNA from each tissue sample was used to generate cDNA with Super Script II reverse transcriptase according to the manufacturer's specifications (Invitrogen). To detect the level of miR-208, RT-PCR was performed with the Taqman MicroRNA assay (Applied Biosystems, ABI) according to the manufacturer's recommendations, using 10 to 100 ng total RNA. The expression of a subset of genes was analyzed by quantitative RT-PCR with Taqman probes purchased from ABI.
Northern Blot Analysis
Total RNA was isolated from cardiac tissue samples by the use of Trizol reagent (Gibco/BRL). Northern blots to detect microRNAs were performed as described previously. A U6 probe served as a loading control (IDT). Total RNA (10 g) from cardiomyocytes or heart tissue was loaded onto 20% acrylamide denaturing gels and transferred to Zeta-probe GT genomic blotting membranes (BioRad) by electrophoresis. After transfer, the blots were cross-linked and baked at 80°C for 1 hour. To maximize the sensitivity of miRNA detection, oligonucleotide probes were labeled with the Starfire Oligos Kit (IDT, Coralville, IA) and ␣-32 P dATP (Amersham or Perkin Elmer). Probes were hybridized to the membranes overnight at 39°C in Rapid-hyb buffer (Amersham); afterward, they were washed twice for 10 minutes at 39°C with 0.5ϫ saline-sodium citrate containing 0.1% SDS. The blots were exposed and quantified by PhosphorImager analysis (GE HealthCare Life Sciences), and a U6 probe served as a loading control (ABI). The intensity of the radioactive signal was used to quantify the fold change in expression with a PhosphorImager and ImageQuant (Bio-Rad).
Western Blot Analysis
For Western blot analysis, myosin was extracted from cardiac cells or tissue as described. 22 Myosin heavy chain isoforms were detected by loading 0.1 g protein lysate on a 4% to 15% gradient gel and separated by SDS-PAGE, and Western blotting was performed with mouse monoclonal anti-myosin (slow, skeletal M8421; Sigma, MO), which is highly specific for Myh7.
Biodistribution Assay
A sandwich hybridization assay was used to quantify antimiR-208a in plasma and tissue samples. Probes for the hybridization assay were synthesized with 2ЈOme and LNA-modified nucleotides and are bTEG-mU;lA;mA;lG;mA;lC;mG (capture probe) and mA;lG;mC;lA;mA;lA;mA;lA;mG-6FAM (detection probe). Detection was accomplished with anti-fluorescence-peroxidase, Fab fragments (Roche), and TMB Peroxidase Substrate (KPL). Standard curves were generated with nonlinear logistic regression analysis with 4 parameters (4-PL). The working concentration range of the assay was 2 to 536 ng/mL. Tissue samples were prepared at 100 mg/mL by homogenizing in 3 mol/L GITC buffer (3 mol/L guanidine isothiocyanate, 0.5 mol/L NaCl, 0.1 mol/L Tris, pH 7.5, and 10 mmol/L EDTA) 2 times for 30 seconds with an MP FastPre-24 at a speed setting of 6.0. Plasma samples and tissue homogenates were diluted a minimum of 50-fold in 1 mol/L GITC Buffer (1 mol/L guanidine isothiocyanate, 0.5 mol/L NaCl, 0.1 mol/L Tris, pH 7.5, and 10 mmol/L EDTA) for testing.
Echocardiography
Cardiac function was evaluated by 2-dimensional transthoracic echocardiography on sedated rats (2%-2.5% isoflurane) using a Visual Sonic Ultrasound system with a 30-MHz transducer. The heart was imaged in a parasternal short-axis view at the level of the papillary muscles to record M-mode measurements and to determine heart rate, wall thickness, and end-diastolic and end-systolic dimensions. Fractional shortening (defined as the end-diastolic dimension minus the end-systolic dimension normalized for the end-diastolic dimension) was used as an index of cardiac contractile function.
Diastolic function was assessed with transmitral flow Doppler from an apical 4-chamber view to measure the E/A ratio, isovolumic relaxation time, and deceleration time of E-wave velocity.
Surface ECG Measurement
Mice were anesthetized with 2% isoflurane in 200 mL/min O 2 , and rats were anesthetized with 2% isoflurane in 500 mL/min breathing air via nosecone. Body temperature for mice and rats was maintained at 37°to 38°C with a Homeothermic Warming System (Kent Scientific) or a heat lamp and warming platform (Visual Sonics). Lead II ECGs were recorded for 10 minutes with subcutaneous needle electrodes and an Iworx data acquisition system sampling at 1 kHz. Using Labscribe software (Iworx), we analyzed tracings after 2, 4, 6, 8, and 10 minutes and inspected them for normal sinus rhythm; Ϸ40 beats at each time point were analyzed by the use of computerized techniques to quantify signal intervals (HR, PR, QRS, QT, and QTc).
Histology
Tissues used for histology were incubated in Krebs-Henseleit solution, fixed in 4% paraformaldehyde, sectioned, and processed for hematoxylin and eosin and Picrosirius Red staining or in situ hybridization by standard techniques. 23 Images of Ϸ100 cardiomyocytes per animal in cross section were captured from the hematoxylin and eosin-stained sections. Cardiomyocyte crosssectional areas were measured with Image-Pro Plus software, and a mean was determined for each animal. Perivascular fibrosis images were taken from epicardial, mid, and endocardial regions from the Picrosirius Red-stained sections from each animal. Image-Pro plus software was used to determine the total vessel wall area, including perivascular fibrosis. The luminal area was subtracted from the total vessel wall area. Perivascular fibrosis was determined via color segmentation and reported as percent of the total vessel wall area.
Gene Expression Analysis
Microarray profiling was performed on Illumina RatRef-12 BeadChip arrays by a service provider (Expression Analysis, Durham, NC). Total RNA was isolated from cardiac tissue as described above. Analysis of differential gene expression was performed by the service provider using permutation analysis of differential expression. Note that if a gene probe does not have detection value of PՅ0.05 in all 12 arrays, then that gene is omitted from subsequent analysis. Differential expression graphs were provided by the service provider. Gene clustering was performed with Cluster 3.0, and heat map images were generated in Java TreeView. Gene ontology was performed with the online tool found at www.pantherdb.org. Predicted miR-208 gene targets in the rat were found with www.targetscan.org (TargetScan), www.pictar.mdc-berlin.de (Pictar), and www.microrna.org (miRanda). Of all the gene targets predicted by miRanda, only those with an mirsvr score of ϽϪ0.1 were included in the analysis. For the identification of miR-208 targets, a cutoff value for differential expression of PՅ0.05 was used.
Quantitative Real-Time Polymerase Chain Reaction Analysis From Plasma
RNA from plasma samples was isolated with Trizol LS Reagent (Invitrogen) following the manufacturer's protocol. Before RNA isolation, we added 250 pmol of 2 different synthetic C. elegans miRNA sequences to serve as internal controls for normalization of target miRNAs. The C. elegans sequences used were cel-miR-2 (UAUCACAGCCAGCUUUGAUGUGC) and cel-lin-4 (UCCCU-GAGACCUCAAGUGUGA) (Dharmacon). The final RNA pellet was resuspended in a final volume equal to the initial plasma volume, and 5 L was used for subsequent RT-PCR reactions, as described above.
Statistical Analysis
One-way ANOVA and the Newman-Keuls multiple comparison post test were used to determine significance. Values of PϽ0.05 were considered statistically significant. For the Kaplan-Meier survival curve, a Mantel-Cox log-rank test was used to determine significance.
Results
Anti-miR-Mediated Silencing of miR-208a In Vivo
To determine the therapeutic potential of miR-208a inhibition in cardiomyocytes in vivo, we designed an LNAcontaining anti-miR targeting bases 2 to 17 of the 5Ј region of mature miR-208a and containing a combination of LNA and DNA linked by phosphorothioate bonds ( Figure 1A ). RT-PCR and Northern blot analysis 1 week after intravenous delivery of antimiR-208a at doses ranging from 0.1 to 33 mg/kg indicated the dose-responsive silencing of miR208a, whereas injection of a mismatch anti-miR of similar chemistry showed no inhibition of miR-208a ( Figure 1B and 1C). Notably, we observed an upshift of miR-208 in the presence of antimiR-208a, reflecting the formation of a stable heteroduplex between miR-208a and the LNA antimiR. Real-time analysis of the other 2 MyomiRs, miR208b and miR-499, showed no inhibition after a single injection after 7 days, nor did we observe any changes in Myh7 (data not shown).
To investigate the potential to deliver antimiR-208a via additional routes of administration, we compared miR-208a inhibition after injection of mice intravenously, intraperitoneally, or subcutaneously with 25 mg/kg antimiR-208a. All 3 routes of administration showed robust inhibition of miR208a at days 1, 4, 7, and 14 ( Figure 1D ), with no significant differences in antimiR-208a detection between the different delivery methods for plasma, heart, liver, or kidney ( Figure I in the online-only Data Supplement).
Prolonged miR-208a Inhibition Leads to Myh7 Regulation In Vivo
Because a single dose of antimiR-208a after 7 days was unable to influence Myh7 expression, we sought to determine the dose and time required for efficient Myh7 regulation after antimiR-208a administration. Three consecutive doses of 33 mg/kg antimiR-208a robustly inhibited miR-208a for at least 6 weeks ( Figure 2A ). miR-499, which is regulated by miR-208, 13 showed a time-dependent decrease in expression from 1 to 6 weeks after administration of antimiR-208a (Figure 2A ). Furthermore, Myh7 expression was significantly reduced starting 4 weeks after antimiR-208a treatment, suggesting that a specific threshold of miR-208a and miR-499 levels is necessary for Myh7 expression ( Figure 2B ), which was paralleled by a reduction in Myh7 protein ( Figure 2C ). The initial spike in Myh7 mRNA in response to antimiR-208a is not translated into increased Myh7 protein ( Figure 2B and 2C) .
To establish whether the effect on Myh7 expression is based on a reduction in both miR-208a and miR-499, we injected mice for 3 consecutive days with a cocktail of antimiR-208a and anti-miR-499, each at 33 mg/kg. Treatment with antimiR-208a/499 caused robust inhibition of miR-208a and miR-499 for 6 weeks and demonstrated a much more rapid regulation of Myh7 mRNA and protein, with reduced expression before 2 weeks after treatment (Figure 2A through 2C) . Consistent with its host gene, miR-208b expression showed a downregulation beginning at 4 weeks ( Figure II in the online-only Data Supplement). Additionally, we used a universal control oligo with the same modifications for this and all subsequent studies, which showed no effects on miR-208a, miR-208b, miR-499, or Myh7, suggesting that the downregulation is due to specific inhibition of miR-208a (Figure 2A through 2C and Figure II in the online-only Data Supplement). Anti-miR distribution data indicated that considerable amounts of antimiR-208a were still detectable in heart, liver, kidney, and plasma 6 weeks after administration of either 33 mg/kg or 3ϫ33 mg/kg of antimiR-208a ( Figure 2D and 2E) .
Therapeutic Silencing of miR-208 Reduces Cardiac Remodeling While Improving Cardiac Function and Survival During Heart Failure
We next aimed to test the therapeutic relevance of miR208a inhibition. To this end, we used Dahl salt-sensitive rats that were fed either a low-salt diet (0.25% NaCl) or a high-salt (HS) diet (8.0% NaCl) starting at 8 weeks of age. Initiation of an HS diet in Dahl salt-sensitive rats results in chronic hypertension, which progresses to a model of congestive heart failure associated primarily with diastolic dysfunction. 24 After 1 week on the HS diet, rats were administered saline, 25 mg/kg antimiR-208a, or 25 mg/kg scrambled control oligo subcutaneously every 2 weeks. After 3 to 4 weeks on the HS diet, the saline-and control-treated animals started to show signs of discomfort and died, whereas subcutaneous delivery of antimiR-208a significantly alleviated these symptoms ( Figure 3A) . As an indication of health, we monitored body weight during the duration of the study. Dahl rats on the HS diet injected with either saline or the control oligo exhibited significant reductions in weight gain compared with controls on the low-salt diet. The HS/antimiR-208a-treated rats, however, showed comparable weight gain ( Figure 3B ). To exclude the possibility that antimiR-208a-treated animals were maintaining weight through ingesting less of the 8% HS diet, food intake was monitored, which showed a comparable ingestion between all HS-fed groups ( Figure III in the online-only Data Supplement).
To obtain additional insight into the basis for the protective effects seen in response to antimiR-208a, subsequent studies were done with a 4.0% NaCl diet during which the rats received saline, 5 or 25 mg/kg of antimiR208a, or 25 mg/kg of anti-miR control every 2 weeks. Body weight analysis indicated that Dahl rats on the HS diet exhibited significant reductions in weight gain compared with the controls on the low-salt diet, whereas the HS/antimiR-208a-treated rats maintained their increase in weight gain ( Figure 3C ). Functional assessment with echocardiography indicated that antimiR-208a-treated rats exhibited a significant dose-dependent reduction in isovolumic relaxation time compared with HS/saline controls, as well as a normalization of the mitral valve early to active filling velocity ratio compared with HS/saline con-trols 8 weeks after the HS diet ( Figure 3D and Figure IV in the online-only Data Supplement). Time-dependent echocardiography performed every 2 weeks after the HS diet showed significant reductions in isovolumic relaxation time in antimiR-208a-treated rats compared with HS/ saline controls ( Figure IV in the online-only Data Supplement). Quantification of cardiomyocyte size showed a significant reduction in cardiomyocyte hypertrophy after treatment with antimiR-208a ( Figure 3E and 3F) . Additionally, antimiR-208a treatment reduced periarteriolar fibrosis induced by the HS diet as assessed by quantification of Picrosirius Red staining ( Figure 3E and 3F) .
miR-208a Inhibition Reverses Myosin Switching During Heart Failure
AntimiR-208a caused a dose-dependent inhibition of miR208a in both left and right ventricles 2 weeks after the last injection with antimiR-208a, whereas a control oligo showed no difference compared with saline ( Figure 4A ). miR-499 also showed a dose-dependent decrease in expression after sustained inhibition of miR-208a ( Figure  4A ). miR-208b was induced in both HS/saline-and HS/control-treated animals, paralleling the upregulation of ␤-myosin heavy chain; however, antimiR-208a treatment resulted in a dose-dependent decrease in miR-208b levels ( Figure 4A ). This regulation of miR-499 and miR-208b was confirmed by Northern blot analysis ( Figure 4B) .
To assess the regulation of the myosin host genes, we examined Myh6, Myh7, and Myh7b mRNA levels. Myh7 was significantly increased in response to HS in both the HS/saline and HS/control groups. This increase was dosedependently blunted in response to antimiR-208a. Additionally, antimiR-208a treatment normalized the decreased expression of Myh6 mRNA observed in both the HS/saline and HS/control groups ( Figure 4C ). Expression of Myh7b mirrored miR-499 levels, exhibiting a dose-dependent reduction on antimiR-208a treatment. Furthermore, the dose-dependent regulation of Myh7 was confirmed by Western blot ( Figure 4D ). In addition, antimiR-208a treatment resulted in a derepression of the previously characterized miR-208a target, HP1␤, further suggesting that antimiR-208a action occurs through miR-208a inhibition ( Figure 4E and Figure V in the online-only Data Supplement).
AntimiR-208a Does Not Induce Changes in Cardiac Conductance or Signs of Toxicity
Although genetic deletion of miR-208a does not affect viability or cause gross morphological heart defects, a previous report mentioned that miR-208a might be required for proper heart electrophysiology. 12 To verify whether antimiR208a treatment resulted in cardiac conductance effects, we measured ECGs in both wild-type mice and diseased rats. Both species showed proper cardiac electrophysiology after antimiR-208a treatment for an extended period of time (Figure VI and Tables I and II in the online-only Data  Supplement) .
Regardless of the route of administration, all mice and rats tolerated the antimiR-208a or control oligo well and exhibited normal behaviors, as determined by activity level and grooming throughout the study. Compared with saline, antimiR-208a or the control oligo did not induce baseline changes in body or tissue weight up to 6 weeks after dosing (Table III) . Neither antimiR-208a nor control oligo treatment changed serum levels of the alanine aminotransferase or aspartate aminotransferase liver enzymes in rats (Figure VII) , suggesting that the oligonucleotides do not induce overt liver toxicities. Therapeutic silencing of miR-208a is beneficial during heart failure. A, Kaplan-Meier survival curves in the Dahl hypertensive rat model show a pronounced decrease in survival in response to an 8% high-salt (HS) diet for both the HS/saline and HS/control groups, which is significantly improved in response to antimiR-208a treatment. Rats were dosed every 2 weeks at 25 mg/kg starting 1 week after the HS diet. *Pϭ0.0038 vs HS/saline; #PϽ0.0001 vs HS/control. B, Body weight analysis indicates that Dahl hypertensive rats on an 8% HS diet exhibit reduced weight gain compared with animals on a low-salt (LS) diet, whereas HS/antimiR-208a-treated rats show a significantly better maintenance in weight gain. For A and B, nϭ6 for LS/saline; nϭ15 for HS/saline and HS/control; and nϭ14 for HS/antimiR-208a. n Indicates total survivors remaining at week 8 after the diet. C, Body weight analysis of Dahl rats on the 4% HS diet shows significant reductions in weight gain compared with LS diet controls, whereas both 5-and 25-mg/kg injections every 2 weeks are sufficient to maintain weight gain comparable to that in animals on a normal diet. D, Echocardiography measurements indicate that the increase in isovolumic relaxation time (IVRT) and decrease in mitral valve early to active filling velocity ratio (MV E/A) in response to a 4% HS diet are significantly improved in response to antimiR-208a treatment 8 weeks after the start of the diet. For C and D, nϭ10 for all groups. E, Representative images of hematoxylin and eosin (H&E)-and Picrosirius Red-stained left ventricular histological sections indicate an increase in cardiomyocyte hypertrophy and perivascular fibrosis in response to the 4% HS diet for 8 weeks, whereas both parameters are reduced in response to antimiR-208a treatment. H&E, scale barϭ50 m; Picrosirius Red, scale barϭ100 m. 
AntimiR-208a Induces Specific Gene Expression Changes
Microarray analysis of hearts of Dahl rats on the HS diet that were injected with saline, antimiR-208a, or control oligo indicated that 131 genes were significantly changed in hearts of antimiR-208a-treated animals compared with control oligo-treated animals ( Figure 5A and Table IV in the online-only Data Supplement). Only 15 genes (with a false-positive discovery rate of 67%) were significantly different between saline-and control oligo-injected animals, indicating that the LNA-modified oligos are highly specific in targeting miR-208a without any gene expression changes induced by the chemistry class ( Figure 5A ). Hierarchical clustering of the expression of the 131 sig- nificantly changed genes between control oligo-and antimiR-208a-treated hearts showed robust clustering of upregulated and downregulated genes after antimiR-208a treatment ( Figure 5B ).
Gene array analysis confirmed the significant downregulation of Myh7 and Myh7b in response to antimiR-208a compared with control oligo (Ϫ1.31, Pϭ0.005; and Ϫ2.38, Pϭ0.037, respectively). Of the 13 518 genes detected on the array, 289 rat genes were bioinformatically predicted to be miR-208 targets. Of these predicted targets, 28 genes showed increased expression with anti-miR-208 treatment by microarray (PϽ0.05), several of which were confirmed by real-time PCR (Figure VIII in the online-only Data Supplement). Upregulation of Dynlt1 was also confirmed by Western blot ( Figure 5C and Figure IX in the onlineonly Data Supplement). Thirteen predicted targets showed decreased expression on the array (PϽ0.05). Seed enrichment analysis with a Kolmogorov-Smirnoff test showed a trend toward derepression of the seed-enriched targets but did not reach significance (data not shown). Because the gene expression analysis was performed on cardiac samples of animals that had been treated with saline, antimiR208a, or control oligo for 8 weeks, we suspect the remainder of the gene expression changes to be secondary to the direct gene regulatory effects of miR-208a inhibition. BLAST analysis of the anti-miR sequence against the rat genome indicated that the sequence of antimiR-208a shows close homology (at least 14 bases of complementarity) to 4 coding sequences; however, none of these genes were regulated on the basis of microarray analysis.
miR-499 Is a Plasma Biomarker for AntimiR-208a Efficacy
Detection of miRNAs in plasma in various disease settings shows increasing diagnostic promise. 25 To determine whether there is a specific miRNA that correlates with antimiR-208a efficacy, we examined a panel of musclerelated miRNAs during HS treatment. Several musclespecific miRNAs did not show significant differences between the groups tested ( Figure X in the online-only Data Supplement). However, miR-499, although showing only modest increases in plasma detection under high salt, was significantly reduced in antimiR-208a-treated animals ( Figure 6 ). Additionally, miR-423-5p plasma levels, which were previously correlated to human heart failure, 26 were found to be reduced in animals treated with antimiR-208a ( Figure 6 ).
Discussion
The results of this study indicate that therapeutic inhibition of miR-208 leads to a reduction in cardiac remodeling, which coincides with a significant improvement in survival and cardiac function during heart disease. Antisense oligonucleotides can be used to effectively silence miRNAs in vivo. [17] [18] [19] [20] [21] These anti-miRs are chemically modified to ensure in vivo stability, specificity, and high binding affinity to the miRNA of interest. A nucleic acid modification, LNA introduces a thermodynamically strong duplex formation with oligonucleotides while enhancing specificity toward complementary RNA or DNA. 17, 18 Because of the high binding affinity, biological activity for LNA-modified anti-miRs is attained with shorter oligonucleotides (8 -16 bases). 27 Recently, the therapeutic applicability of systemically delivered LNAmodified anti-miRs has been reported in nonhuman primates, in which inhibition of the liver-expressed miR-122 led to an improvement in hepatitis C virus-induced liver pathology in chronically infected chimpanzees. 21 Furthermore, it has recently been shown that anti-miR length can be altered, even down to 8 bases, with sustained inhibition. 28 We have tested additional lengths of anti-miRs; however, the 16-mer used here was the most efficacious in cardiac inhibition (data not shown). We believe that anti-miR length selection will be miRNA dependent, with A/U composition and copy number being factors.
A key finding in the present study is that systemic delivery of LNA-modified oligonucleotides is effective in inducing potent and sustained silencing of miR-208 in the heart. Sustained miR-208a inhibition and the absence of an effect on the closely related miR-208b, which differs by only 2 bp in the targeted region ( Figure XI in the online-only Data Supplement), on systemic delivery of antimiR-208a indicate in vivo stability and specificity. We have further confirmed reciprocal specificity in which an anti-miR against miR-208b showed no miR-208a inhibition (data not shown). From the persistent miR-208a silencing and the downstream Myh7 regulation over time, it seems probable that antimiR-208a can accumulate in cardiac cells to silence all newly formed copies of miR208a that are being produced by Myh6 transcription. This effect might be reinforced further by the general lack of turnover of cardiomyocytes, preventing dilution owing to a decrease in the portion of cells that are targeted with the anti-miR.
Although gene regulatory effects of miRNAs on direct targets are fairly immediate, miR-208a inhibition requires several weeks before it establishes an effect on Myh7b and Myh7 expression, as well as their intronic miRNAs, miR-499 and miR-208b, respectively. Although miR-208b and Myh7 levels follow the same trend in downregulation, we recognize moderate differences in expression, which are likely due to stability differences and to differences in posttranscriptional regulation. We hypothesize that the delay in downstream biological effects is due to the requirement of alterations in the expression of many direct and indirect target genes of which the combined effects are required to induce the change. Given the modest and fine-tuning nature of miRNA regulation of many target genes, it likely takes some time to readjust the system after miRNA removal. miR-208 targets repressor proteins that are likely to contribute to Myh7 regulation and cardiac remodeling. 13 A comparable phenomenon was observed in response to miR-122 inhibition, which induces a lowering in plasma cholesterol, but not until several weeks after anti-miR treatment. 17, 18 Nonetheless, the effect on Myh7b and Myh7 expression phenocopies the genetic deletion of miR-208a, 11, 12 indicating that miR-208a is effectively silenced.
The therapeutic effects of antimiR-208a in the Dahl hypertensive rat provide strong evidence that subcutaneous delivery of LNA-based anti-miRs is sufficient to deliver anti-miRs effectively to the heart in vivo, and that miR208a inhibition prevents cardiac remodeling, blunts functional deterioration, and delays lethality during heart disease. Currently, it remains unclear whether these effects arise solely from effects on cardiomyocytes as a result of miR-208a inhibition or whether there are extracardiac effects in response to miR-208a inhibition. However, the cardiomyocyte-specific expression of miR-208a, the dose responsiveness, and the absence of an effect in animals treated with a control chemistry strongly suggest that the observed effects are due to a lowering in miR-208a levels. Ongoing experiments will indicate whether this therapeutic benefit can be established in multiple models of heart failure.
Although the initial rodent data are encouraging and no adverse side effects were observed on anti-miR treatment, extensive analyses are required to determine the long-term safety of such agents in various settings. Comparable antimiR chemistries are currently being evaluated in the first human clinical trials of miRNA inhibition (Santaris Pharma; www.clinicaltrials.gov).
Recently, miRNAs were detected in serum and plasma of humans and animals, suggesting the possibility of using miRNAs as diagnostic biomarkers of various diseases, including heart disease. 26,29 -31 Plasma miRNA analysis shows that antimiR-208a treatment results in a diminution of miR-499 in blood serum, which parallels the decrease in cardiac expression of Myh7b/miR-499 in response to antimiR-208a treatment. Given the correlation between cardiac-and plasma-based miR-499 levels and the efficacy of antimiR-208a, these data suggest that plasma miR-499 levels might serve as a biomarker of effective delivery of antimiR-208a to the heart when moving into patients.
Myosin and subsequent MyomiR expression differs significantly between species. Whereas Myh6/miR-208a is the predominant myosin/MyomiR isoform in the hearts of rodents, larger mammals express more Myh7/miR208b. 16 Although miR-208a and miR-208b have overlapping seed sequence, they differ by 3 bases in their 3Ј region ( Figure  VII in the online-only Data Supplement). Subsequent pharmacokinetic and efficacy studies in larger mammals are required to establish whether inhibition of miR-208a, miR-208b, or both is required to establish a comparable therapeutic effect in larger species. Additionally, because therapeutic use of miR-208 inhibition will likely be a combination therapy with current standard of care in heart failure patients, it will be important to assess whether antimiR-208a, in conjunction with current treatments, adds to the beneficial effects of these drugs. Taken together, this study demonstrates that subcutaneous delivery of LNAbased anti-miRs can effectively target the heart and further validates miR-208 as a target during cardiac disease.
